Overview of treatment use and doses at −1 year, inclusion and +1 year
| −1 year | Inclusion | +1 year | ||||
|---|---|---|---|---|---|---|
| Treatment | n (%) | Mean±SD (mg/day) | n (%) | Mean±SD (mg/day) | n (%) | Mean±SD (mg/day) |
| GC | 63 (56.8) | 5.9±2.5 | 66 (59.5) | 6.3±3.9 | 64 (57.7) | 7.7±7.8 |
| HCQ | 46 (41.4) | 251.0±91.2 | 52 (46.8) | 232.9±81.1 | 45 (40.5) | 247.2±86.4 |
| AZA | 28 (25.2) | 115.4±41.2 | 21 (18.9) | 104.0±40.1 | 23 (20.7) | 103.3±33.1 |
| MTX | 8 (7.2) | 13.1±6.6 | 9 (8.1) | 15.3±4.8 | 7 (6.3) | 14.7±6.2 |
| MMF | 8 (7.2) | 1406.3±581.5 | 8 (7.2) | 1068.8±628.5 | 6 (5.4) | 1041.7±510.3 |
| CyA | 6 (5.4) | 159.2±34.7 | 6 (5.4) | 176.7±97.3 | 6 (5.4) | 133.3±40.8 |
| CYC | 0 (0) | – | 1 (0.9) | 700* | 0 (0) | – |
| GC pulse | 0 (0) | – | 0 (0) | – | 0 (0) | – |
*mg/month during 6 months.
AZA, azathioprine; CyA, cyclosporin A; CYC, cyclophosphamide; GC, glucocorticoid; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; MTX, methotrexate.